A Phase 3 interventional study of Experimental : Secukinumab low dose and Experimental: Secukinumab high dose in Chronic Severe Plaque-type Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 46 sites in 19 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-10-11.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Psoriasis by Novartis — 3 open to participants now, 4 under way, none of them phase 3. Psoriasis · Novartis.
Among the 68 studies in Psoriasis by Novartis, this one is the 28th largest by enrollment of the 53 interventional ones that give a count, is one of 8 that started in 2015, is one of 30 in phase 3, and was the 36th registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →3 of the 68 studies in Psoriasis by Novartis are open now, in 3 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Novartis Pharmaceuticals · Sites in Spain
Ages 18–100
Novartis Pharmaceuticals · Sites in Canada
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 174 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 41 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 30 · Phase 4 6
First in 2004; this study’s year is marked. 8 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 162 is above the median of 75 across 1,568 interventional studies indexed under Psoriasis.
Median enrollment 177 across the 53 interventional studies, 255 across the 14 observational. Of the 61 that completed or were terminated, 41 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
3 of the studies in Psoriasis by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06382051Novartis PharmaceuticalsModifying PEST for Psoriatic Arthritis Screening | 2026-12-31 |
| NCT07683065Novartis PharmaceuticalsA Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD | 2027-01-15 |
| NCT06142357Novartis PharmaceuticalsSecukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 68 studies in Psoriasis by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a multicenter, randomized, double-blind, placebo- and active-controlled (etanercept in single blinded arm) study in pediatric subjects aged 6 years to less than 18 years with severe chronic plaque psoriasis. Approximately 160 subjects aged 6 years to \<18 years were enrolled, of which at least 30 were 6 years to \<12 years old. Subjects were enrolled at approximately 70 study sites worldwide.
The purpose of this study was to demonstrate superior efficacy of secukinumab versus placebo at Week 12, based on both PASI 75 and IGA mod 2011 0 or 1 response rates in children and adolescents aged 6 to less than 18 years with severe chronic plaque psoriasis who had inadequate control of symptoms with topical treatment, or failed to respond to or tolerate previous systemic treatment and/or UV therapy
The study assessed the long term safety and tolerability of secukinumab in this pediatric age group and described the efficacy and safety of secukinumab compared to etanercept. This study provided efficacy and safety data to support the extension of label of secukinumab to include children and adolescents (6 years to \<18 years) with severe chronic plaque psoriasis
Two age subgroups were studied in a staggered approach within this clinical study: 12 to less than 18 years of age, and 6 to less than 12 years of age . Enrolment of children aged 6 to less than 12 years began after a favorable recommendation by an independent external Data Monitoring Committee (DMC) who reviewed data of approximately 80 adolescents. Adolescents continued to be recruited while the data from the first 80 subjects was being collected and analyzed
Subjects were randomized using a 1:1:1:1 ratio into one of the treatment arms: secukinumab low dose, secukinumab high dose, etanercept or placebo. Subjects randomized to secukinumab treatment arms (high dose and low dose) received dose based on the weight category (\<25 kg, 25 to \<50kg, ≥50 kg).
The study consisted of 5 periods: screening (up to 4 weeks), induction (of 12 weeks), maintenance (of 40 weeks), extension treatment epoch (open-label of 184 weeks) and post- treatment follow-up epoch (of 16 weeks).
The screening period of up to 4 weeks was used to assess eligibility of the patients and to taper patients off prohibited medications.
The Induction period is defined as randomization through Week 12. In this period, the study was both active and placebo-controlled and at its completion, the primary endpoint was assessed (Week 12).
The Maintenance period is defined as Week 12 (from dosing) through Week 52. During this period, the study was active-controlled, and the objectives focused on the maintenance of the response observed at Week 12.
Patients who received secukinumab or etanercept during induction continued in maintenance with the same treatment. Patients who were on placebo during induction and at Week 12 were PASI 75 non-responders were switched to either secukinumab low dose or secukinumab high dose treatment group in the Maintenance period according to their baseline randomization.
At the end of the Maintenance period, all patients on secukinumab entered the Extension treatment period and continued to receive the same dose of secukinumab. The Extension treatment period was defined as Week 52 (from dosing) until Week 236. In this period, all patients were treated with secukinumab, and the purpose was the collection of long-term safety and efficacy data.
Patients who participated in the Maintenance period but prematurely discontinued the study were not able to enter the Extension treatment period. Patients receiving etanercept were not eligible to enter the Extension treatment period. Instead, at Week 52, they completed an EOM visit and then entered the post-treatment Follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Severe plaque-type psoriasis meeting all of the following three criteria:
Patient being regarded by the investigator to be a candidate for systemic therapy because of:
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Secukinumab
Biological: Experimental : Secukinumab low dose
Secukinumab
Biological: Experimental: Secukinumab high dose
Placebo
Biological: Placebo Comparator: Secukinumab Placebo
Etanercept
Biological: Active Comparator: Etanercept
Depending on weight group subject will receive per dose a) 75 mg if weighing less than 50 kg b) 150 mg if weighing 50 kg or more. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
Also known as: AIN457 low dose
Depending on weight group subject will receive per dose a) 75 mg if weighing less than 25 kg b) 150 mg if weighing between 25 and less than 50 kg c) 300 mg if weighing more than 50 kg. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
Also known as: AIN457 high dose
Placebo secukinumab (one or two subcutaneous injections per dose, depending on weight group) at Randomization and Weeks 1, 2, 3 4 and 8. At Week 12, subjects in the placebo group based on their PASI 75 response status at Week 12 will proceed as follows: • PASI 75 responders will discontinue study treatment at Week 12 and enter the treatment-free follow-up period • PASI 75 non-responders will receive high dose or low dose secukinumab, according to the pre-assignment at the Randomization visit. They will receive their treatment based on the weight category(\<25 kg, 25- \<50kg, ≥50 kg), on Weeks 12, 13, 14, 15, and then every four weeks starting at Week 16 until Week 48 during the maintenance period; thereafter at week 52 and every 4 weeks during the extension treatment period until Week 232.
Also known as: AIN457 placebo
Etanercept 0.8 mg/kg of subject weight and up to a maximum of 50 mg per dose. Subcutaneous etanercept 0.8 mg/kg (one or two injections per dose) once per week, for 51 weeks administered at home (self-injected or by caregiver) or at the study site. At Wk 52 subjects in the etanercept group will move into the treatment-free follow up period and terminate the study.
Also known as: Etanercept
Number and Percentage of Participants Achieving a 75% Improvement From Baseline in PASI Score at Week 12
Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 75 represents the percentage (or number) of patients who have achieved a 75% or more reduction in their PASI score from baseline.
Time frame: 12 weeks
Number and Percentage of Participants Who Showed Investigator's Global Assessment (IGA) Mod 2011 Response of 0 or 1 at Week 12
IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe
Time frame: 12 Weeks
Number and Percentage of Participants Achieving a 90% Improvement From Baseline in PASI Score at Week 12
Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 90 represents the percentage (or number) of patients who have achieved a 90% or more reduction in their PASI score from baseline.
Time frame: 12 weeks
Number and Percentage of Participants Achieving a 50%, 100% Improvement From Baseline in PASI Score at Week 12
Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 50 represents the percentage (or number) of patients who have achieved a 50% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.
Time frame: 12 weeks
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 up to Week 12 (Induction)
Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema, Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). PASI will be assessed/calculated as per standard procedure. IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe
Time frame: Weeks 4, 8
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance)
Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema, Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). PASI will be assessed/calculated as per standard procedure. IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe
Time frame: Weeks 16, 20, 24, 36, 48 and 52
Change From Baseline in Psoriasis Area & Severity Index (PASI) Score at Week 12
Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 75 represents the percentage (or number)of patients who have achieved a 75% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.
Time frame: Week 12
Change From Baseline in Psoriasis Area & Severity Index (PASI) Scores at Week 52
Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 75 represents the percentage (or number)of patients who have achieved a 75% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.
Time frame: Week 52
Percentage of Participants in IGA Mod 2011 Score Categories at Week 12
IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe
Time frame: Week 12
Percentage of Participants in IGA Mod 2011 Score Categories at Week 52
IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe
Time frame: Week 52
Percentage Change From Baseline in Children's Dermatology Life Quality Index (cDLQI) Score Up to Week 12 (Induction)
The CDLQI measures functional disability of subjects with dermatological disorders who are less than 18 years of age and it has been utilized as a relevant clinical measure in atopic dermatitis, as well as other dermatitis clinical trials. The CDLQI is a simple, validated, self-administered 10-item questionnaire. The instrument contains six functional scales (i.e., symptoms and feeling, leisure, school or holidays, personal relationships, sleep and treatment). The questions are based on the preceding week to permit accurate recall. For the CDLQI, each question will be answered on a 4-point Likert scale scored from 0 to 3. Seven scores will be derived from the CDLQI: the total score of each of the six dimensions as well as the total score over all items. The higher the score, the more quality of life is impaired.
Time frame: Weeks 4, 8, 12
Percentage Change From Baseline in Children's Dermatology Life Quality Index (cDLQI) Score Up to Week 52 (Maintenance)
The CDLQI measures functional disability of subjects with dermatological disorders who are less than 18 years of age and it has been utilized as a relevant clinical measure in atopic dermatitis, as well as other dermatitis clinical trials. The CDLQI is a simple, validated, self-administered 10-item questionnaire. The instrument contains six functional scales (i.e., symptoms and feeling, leisure, school or holidays, personal relationships, sleep and treatment). The questions are based on the preceding week to permit accurate recall. For the CDLQI, each question will be answered on a 4-point Likert scale scored from 0 to 3. Seven scores will be derived from the CDLQI: the total score of each of the six dimensions as well as the total score over all items. The higher the score, the more quality of life is impaired.
Time frame: Weeks 24, 36, 52
Number and Percentage of Participants Achieving a Children's DLQI Score of 0 or 1 Over Time up to Week 12 (Induction)
The CDLQI measures functional disability of subjects with dermatological disorders who are less than 18 years of age and it has been utilized as a relevant clinical measure in atopic dermatitis, as well as other dermatitis clinical trials. The CDLQI is a simple, validated, self-administered 10-item questionnaire. The instrument contains six functional scales (i.e., symptoms and feeling, leisure, school or holidays, personal relationships, sleep and treatment). The questions are based on the preceding week to permit accurate recall. For the CDLQI, each question will be answered on a 4-point Likert scale scored from 0 to 3. Seven scores will be derived from the CDLQI: the total score of each of the six dimensions as well as the total score over all items. The higher the score, the more quality of life is impaired.
Time frame: Weeks 4, 8, 12
Number and Percentage of Participants Achieving a Children's DLQI Score of 0 or 1 Over Time up to Week 52 (Maintenance)
The CDLQI measures functional disability of subjects with dermatological disorders who are less than 18 years of age and it has been utilized as a relevant clinical measure in atopic dermatitis, as well as other dermatitis clinical trials. The CDLQI is a simple, validated, self-administered 10-item questionnaire. The instrument contains six functional scales (i.e., symptoms and feeling, leisure, school or holidays, personal relationships, sleep and treatment). The questions are based on the preceding week to permit accurate recall. For the CDLQI, each question will be answered on a 4-point Likert scale scored from 0 to 3. Seven scores will be derived from the CDLQI: the total score of each of the six dimensions as well as the total score over all items. The higher the score, the more quality of life is impaired.
Time frame: Weeks 24, 36, 52
Number and Percentage of Participants With Clinically Important Reduction in Disability as Evaluated by CHAQ Questionnaire Over Time at Week 12
The CHAQ questionnaire is only done for children who in addition to psoriasis are also suffering from psoriatic arthritis. The questionnaire is completed by parent or legal guardian. It consists of multiple choice items concerning difficulty in performing eight common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and other "activities". The person completing the questionnaire chooses from four response categories, ranging from 'without any difficulty' to 'unable to do'. Additionally two visual analog scales (overall well-being and pain of patient) must be performed.
Time frame: Week 12
Number and Percentage of Participants With Clinically Important Reduction in Disability as Evaluated by CHAQ Questionnaire Over Time at Week 52
The CHAQ questionnaire is only done for children who in addition to psoriasis are also suffering from psoriatic arthritis. The questionnaire is completed by parent or legal guardian. It consists of multiple choice items concerning difficulty in performing eight common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and other "activities". The person completing the questionnaire chooses from four response categories, ranging from 'without any difficulty' to 'unable to do'. Additionally two visual analog scales (overall well-being and pain of patient) must be performed.
Time frame: Week 52
This was a multicenter, randomized, double-blind, placebo- and active-controlled (etanercept in single blinded arm) study in pediatric patients aged 6 years to less than 18 years with severe chronic plaque psoriasis. A total of 187 patients were screened, of which 162 were randomized.
| Milestone | AIN457 Low Dose (Induction Period) | AIN457 High Dose (Induction Period) | Placebo (Induction Period) | Etanercept Comparator (Induction Period) | AIN457 Low Dose (Maintenance Period) | AIN457 High Dose (Maintenance Period) | Placebo-AIN457 Low Dose (Maintenance Period) | Placebo-AIN457 High Dose (Maintenance Period | Etanercept Comparator (Maintenance Period) | Any AIN457 Low Dose (Extension Period) | Any AIN457 High Dose (Extension Period) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 40 | 40 | 41 | 41 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 39 | 38 | 39 | 40 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Subject/guardian decision | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | AIN457 Low Dose (Induction Period) | AIN457 High Dose (Induction Period) | Placebo (Induction Period) | Etanercept Comparator (Induction Period) | AIN457 Low Dose (Maintenance Period) | AIN457 High Dose (Maintenance Period) | Placebo-AIN457 Low Dose (Maintenance Period) | Placebo-AIN457 High Dose (Maintenance Period | Etanercept Comparator (Maintenance Period) | Any AIN457 Low Dose (Extension Period) | Any AIN457 High Dose (Extension Period) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 39 | 38 | 16 | 18 | 40 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 38 | 37 | 15 | 16 | 34 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 6 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 |
| Milestone | AIN457 Low Dose (Induction Period) | AIN457 High Dose (Induction Period) | Placebo (Induction Period) | Etanercept Comparator (Induction Period) | AIN457 Low Dose (Maintenance Period) | AIN457 High Dose (Maintenance Period) | Placebo-AIN457 Low Dose (Maintenance Period) | Placebo-AIN457 High Dose (Maintenance Period | Etanercept Comparator (Maintenance Period) | Any AIN457 Low Dose (Extension Period) | Any AIN457 High Dose (Extension Period) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 53 | 53 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 39 | 43 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 10 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 3 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Withdrew: Technical problems | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Subject/guardian decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 |
Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 75 represents the percentage (or number) of patients who have achieved a 75% or more reduction in their PASI score from baseline.
| Participants | AIN457 Low Dose | AIN457 High Dose | Placebo | Etanercept |
|---|---|---|---|---|
| Number and Percentage of Participants Achieving a 75% Improvement From Baseline in PASI Score at Week 12 | 32 | 31 | 6 | 26 |
IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe
| Participants | AIN457 Low Dose | AIN457 High Dose | Placebo | Etanercept |
|---|---|---|---|---|
| Number and Percentage of Participants Who Showed Investigator's Global Assessment (IGA) Mod 2011 Response of 0 or 1 at Week 12 | 28 | 24 | 2 | 14 |
Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 90 represents the percentage (or number) of patients who have achieved a 90% or more reduction in their PASI score from baseline.
| Participants | AIN457 Low Dose | AIN457 High Dose | Placebo | Etanercept |
|---|---|---|---|---|
| Number and Percentage of Participants Achieving a 90% Improvement From Baseline in PASI Score at Week 12 | 29 | 27 | 1 | 12 |
Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 50 represents the percentage (or number) of patients who have achieved a 50% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.
| Participants | AIN457 Low Dose | AIN457 High Dose | Placebo | Etanercept |
|---|---|---|---|---|
| PASI 50 | 34 | 34 | 9 | 34 |
| PASI 100 | 12 | 11 | 0 | 7 |
Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema, Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). PASI will be assessed/calculated as per standard procedure. IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe
| Participants | AIN457 Low Dose | AIN457 High Dose | Placebo | Etanercept |
|---|---|---|---|---|
| Week 4- IGA 0/1 | 6 | 13 | 0 | 1 |
| Week 4- PASI 50 | 26 | 28 | 6 | 19 |
| Week 4- PASI 75 | 13 | 22 | 0 | 5 |
| Week 4- PASI 90 | 5 | 9 | 0 | 1 |
| Week 4- PASI 100 | 3 | 3 | 0 | 0 |
| Week 8- IGA 0/1 | 21 | 18 | 0 | 6 |
| Week 8- PASI 50 | 32 | 32 | 11 | 30 |
| Week 8- PASI 75 | 27 | 26 | 1 | 15 |
| Week 8- PASI 90 | 20 | 20 | 0 | 4 |
| Week 8-PASI 100 | 9 | 7 | 0 | 2 |
Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema, Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). PASI will be assessed/calculated as per standard procedure. IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe
| Participants | AIN457 Low Dose | AIN457 High Dose | Placebo-AIN457 Low Dose | Placebo- AIN457 High Dose | Etanercept |
|---|---|---|---|---|---|
| Week 16- IGA 0/1 | 32 | 28 | 5 | 8 | 19 |
| Week 16- PASI 50 | 37 | 35 | 11 | 16 | 30 |
| Week 16- PASI 75 | 36 | 32 | 5 | 11 | 26 |
| Week 16- PASI 90 | 33 | 30 | 4 | 7 | 16 |
| Week 16- PASI 100 | 19 | 14 | 0 | 1 | 8 |
| Week 20- IGA 0/1 | 33 | 28 | 12 | 13 | 21 |
| Week 20- PASI 50 | 38 | 36 | 15 | 17 | 32 |
| Week 20- PASI 75 | 38 | 35 | 13 | 15 | 29 |
| Week 20- PASI 90 | 33 | 30 | 12 | 12 | 19 |
| Week 20- PASI 100 | 20 | 16 | 5 | 4 | 8 |
| Week 24- IGA 0/1 | 35 | 30 | 14 | 14 | 20 |
| Week 24- PASI 50 | 38 | 37 | 15 | 16 | 31 |
| Week 24- PASI 75 | 37 | 35 | 15 | 14 | 26 |
| Week 24- PASI 90 | 33 | 31 | 13 | 12 | 19 |
| Week 24- PASI 100 | 22 | 17 | 7 | 6 | 9 |
| Week 36- IGA 0/1 | 32 | 29 | 14 | 14 | 21 |
| Week 36- PASI 50 | 37 | 37 | 16 | 16 | 31 |
| Week 36- PASI 75 | 35 | 35 | 16 | 16 | 26 |
| Week 36-PASI 90 | 32 | 31 | 10 | 7 | 18 |
| Week 36-PASI 100 | 17 | 20 | 10 | 7 | 10 |
| Week 48- IGA 0/1 | 28 | 28 | 14 | 14 | 21 |
| Week 48-PASI 50 | 38 | 35 | 15 | 15 | 31 |
| Week 48- PASI 75 | 35 | 35 | 14 | 15 | 27 |
| Week 48- PASI 90 | 29 | 30 | 12 | 14 | 23 |
| Week 48- PASI 100 | 16 | 18 | 10 | 8 | 12 |
| Week 52- 1GA 0/1 | 29 | 30 | 14 | 13 | 23 |
| Week 52- PASI 50 | 39 | 37 | 15 | 17 | 32 |
| Week 52- PASI 75 | 35 | 35 | 14 | 17 | 28 |
| Week 52- PASI 90 | 30 | 32 | 13 | 14 | 21 |
| Week 52- PASI 100 | 16 | 19 | 10 | 10 | 9 |
Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 75 represents the percentage (or number)of patients who have achieved a 75% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.
| Scores on a scale | AIN457 Low Dose | AIN457 High Dose | Placebo | Etanercept |
|---|---|---|---|---|
| Change From Baseline in Psoriasis Area & Severity Index (PASI) Score at Week 12 | -22.27 ± 8.518 | -22.67 ± 11.904 | -7.94 ± 9.396 | -20.91 ± 10.055 |
Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 75 represents the percentage (or number)of patients who have achieved a 75% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.
| Scores on a scale | AIN457 Low Dose | AIN457 High Dose | Placebo-AIN457 Low Dose | Placebo-AIN457 High Dose | Etanercept |
|---|---|---|---|---|---|
| Change From Baseline in Psoriasis Area & Severity Index (PASI) Scores at Week 52 | -25.26 ± 7.150 | -25.75 ± 8.593 | -28.49 ± 7.984 | -24.69 ± 5.520 | -21.16 ± 11.779 |
IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe
| Participants | AIN457 Low Dose | AIN457 High Dose | Placebo | Etanercept |
|---|---|---|---|---|
| Week 12- IGA Category: Clear | 12 | 11 | 0 | 7 |
| Week 12- IGA Category: Almost Clear | 14 | 13 | 2 | 7 |
| Week 12- IGA Category: Mild Disease | 8 | 7 | 4 | 18 |
| Week 12- IGA Category: Moderate Disease | 3 | 4 | 11 | 6 |
| Week 12- IGA Category: Severe Disease | 2 | 4 | 23 | 3 |
IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe
| Participants | AIN457 Low Dose | AIN457 High Dose | Placebo-AIN457 Low Dose | Placebo-AIN457 High Dose | Etanercept |
|---|---|---|---|---|---|
| Week 52- IGA Category: Clear | 16 | 20 | 10 | 10 | 9 |
| Week 52- IGA Category: Almost Clear | 13 | 10 | 4 | 4 | 14 |
| Week 52- IGA Category: Mild Disease | 7 | 4 | 2 | 4 | 9 |
| Week 52- IGA Category: Moderate Disease | 2 | 2 | 0 | 0 | 4 |
| Week 52- IGA Category: Severe Disease | 1 | 3 | 0 | 0 | 5 |
The CDLQI measures functional disability of subjects with dermatological disorders who are less than 18 years of age and it has been utilized as a relevant clinical measure in atopic dermatitis, as well as other dermatitis clinical trials. The CDLQI is a simple, validated, self-administered 10-item questionnaire. The instrument contains six functional scales (i.e., symptoms and feeling, leisure, school or holidays, personal relationships, sleep and treatment). The questions are based on the preceding week to permit accurate recall. For the CDLQI, each question will be answered on a 4-point Likert scale scored from 0 to 3. Seven scores will be derived from the CDLQI: the total score of each of the six dimensions as well as the total score over all items. The higher the score, the more quality of life is impaired.
| percentage change of score | AIN457 Low Dose | AIN457 High Dose | Placebo | Etanercept |
|---|---|---|---|---|
| Week 4 | -47.71 ± 45.743 | -50.71 ± 37.003 | 1.67 ± 104.216 | -35.13 ± 56.832 |
| Week 8 | -61.60 ± 54.371 | -66.97 ± 32.040 | -17.77 ± 66.451 | -42.73 ± 54.026 |
| Week 12 | -67.43 ± 41.602 | -62.5 ± 50.08 | -18.48 ± 80.018 | -62.80 ± 34.419 |
The CDLQI measures functional disability of subjects with dermatological disorders who are less than 18 years of age and it has been utilized as a relevant clinical measure in atopic dermatitis, as well as other dermatitis clinical trials. The CDLQI is a simple, validated, self-administered 10-item questionnaire. The instrument contains six functional scales (i.e., symptoms and feeling, leisure, school or holidays, personal relationships, sleep and treatment). The questions are based on the preceding week to permit accurate recall. For the CDLQI, each question will be answered on a 4-point Likert scale scored from 0 to 3. Seven scores will be derived from the CDLQI: the total score of each of the six dimensions as well as the total score over all items. The higher the score, the more quality of life is impaired.
| percentage change of score | AIN457 Low Dose | AIN457 High Dose | Placebo-AIN457 Low Dose | Placebo-AIN457 High Dose | Etanercept |
|---|---|---|---|---|---|
| Week 24 | -73.7 ± 55.02 | -53.9 ± 74.63 | 40.3 ± 477.93 | -73.8 ± 53.09 | -55.0 ± 44.98 |
| Week 36 | -79.0 ± 31.99 | -56.2 ± 107.65 | -89.5 ± 19.11 | -69.4 ± 46.46 | -47.7 ± 45.01 |
| Week 52 | -80.9 ± 39.38 | -58.6 ± 77.56 | -89.0 ± 15.73 | -86.0 ± 23.19 | -53.4 ± 56.99 |
The CDLQI measures functional disability of subjects with dermatological disorders who are less than 18 years of age and it has been utilized as a relevant clinical measure in atopic dermatitis, as well as other dermatitis clinical trials. The CDLQI is a simple, validated, self-administered 10-item questionnaire. The instrument contains six functional scales (i.e., symptoms and feeling, leisure, school or holidays, personal relationships, sleep and treatment). The questions are based on the preceding week to permit accurate recall. For the CDLQI, each question will be answered on a 4-point Likert scale scored from 0 to 3. Seven scores will be derived from the CDLQI: the total score of each of the six dimensions as well as the total score over all items. The higher the score, the more quality of life is impaired.
| Participants | AIN457 Low Dose | AIN457 High Dose | Placebo | Etanercept |
|---|---|---|---|---|
| Week 4 | 8 | 11 | 2 | 9 |
| Week 8 | 15 | 19 | 7 | 10 |
| Week 12 | 17 | 19 | 6 | 15 |
The CDLQI measures functional disability of subjects with dermatological disorders who are less than 18 years of age and it has been utilized as a relevant clinical measure in atopic dermatitis, as well as other dermatitis clinical trials. The CDLQI is a simple, validated, self-administered 10-item questionnaire. The instrument contains six functional scales (i.e., symptoms and feeling, leisure, school or holidays, personal relationships, sleep and treatment). The questions are based on the preceding week to permit accurate recall. For the CDLQI, each question will be answered on a 4-point Likert scale scored from 0 to 3. Seven scores will be derived from the CDLQI: the total score of each of the six dimensions as well as the total score over all items. The higher the score, the more quality of life is impaired.
| Participants | AIN457 Low Dose | AIN457 High Dose | Placebo-AIN457 Low Dose | Placebo-AIN457 High Dose | Etanercept |
|---|---|---|---|---|---|
| Week 24 | 19 | 17 | 8 | 9 | 17 |
| Week 36 | 21 | 21 | 9 | 8 | 12 |
| Week 52 | 20 | 22 | 8 | 11 | 16 |
The CHAQ questionnaire is only done for children who in addition to psoriasis are also suffering from psoriatic arthritis. The questionnaire is completed by parent or legal guardian. It consists of multiple choice items concerning difficulty in performing eight common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and other "activities". The person completing the questionnaire chooses from four response categories, ranging from 'without any difficulty' to 'unable to do'. Additionally two visual analog scales (overall well-being and pain of patient) must be performed.
| Participants | AIN457 Low Dose | AIN457 High Dose | Placebo | Etanercept |
|---|---|---|---|---|
| Number and Percentage of Participants With Clinically Important Reduction in Disability as Evaluated by CHAQ Questionnaire Over Time at Week 12 | 2 | 0 | 0 | 2 |
The CHAQ questionnaire is only done for children who in addition to psoriasis are also suffering from psoriatic arthritis. The questionnaire is completed by parent or legal guardian. It consists of multiple choice items concerning difficulty in performing eight common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and other "activities". The person completing the questionnaire chooses from four response categories, ranging from 'without any difficulty' to 'unable to do'. Additionally two visual analog scales (overall well-being and pain of patient) must be performed.
| Participants | AIN457 Low Dose | AIN457 High Dose | Placebo- AIN457 Low Dose | Placebo- AIN457 High Dose | Etanercept |
|---|---|---|---|---|---|
| Number and Percentage of Participants With Clinically Important Reduction in Disability as Evaluated by CHAQ Questionnaire Over Time at Week 52 | 2 | 0 | 1 | 0 | 2 |
Collected over Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Any AIN457 Low Dose | 0/56 (0%) | 7/56 (12.5%) | 48/56 (85.7%) |
| Any AIN457 High Dose | 0/58 (0%) | 8/58 (13.8%) | 50/58 (86.2%) |
| Any AIN457 Dose | 0/114 (0%) | 15/114 (13.2%) | 98/114 (86%) |
| Placebo | 0/41 (0%) | 0/41 (0%) | 19/41 (46.3%) |
| Etanercept | 0/41 (0%) | 6/41 (14.6%) | 30/41 (73.2%) |
| Event | Any AIN457 Low Dose | Any AIN457 High Dose | Any AIN457 Dose | Placebo | Etanercept |
|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/56 | 0/58 | 0/114 | 0/41 | 1/41 |
| Autoimmune pancreatitisGastrointestinal disorders | 0/56 | 0/58 | 0/114 | 0/41 | 1/41 |
| Gastrointestinal toxicityGastrointestinal disorders | 0/56 | 0/58 | 0/114 | 0/41 | 1/41 |
| Gallbladder polypHepatobiliary disorders | 0/56 | 0/58 | 0/114 | 0/41 | 1/41 |
| Pilonidal diseaseInfections and infestations | 0/56 | 0/58 | 0/114 | 0/41 | 1/41 |
| SyncopeNervous system disorders | 0/56 | 0/58 | 0/114 | 0/41 | 1/41 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 0/56 | 0/58 | 0/114 | 0/41 | 1/41 |
| BronchitisInfections and infestations | 1/56 | 0/58 | 1/114 | 0/41 | 0/41 |
| CellulitisInfections and infestations | 1/56 | 0/58 | 1/114 | 0/41 | 0/41 |
| Alanine aminotransferase increasedInvestigations | 1/56 | 0/58 | 1/114 | 0/41 | 0/41 |
| Event | Any AIN457 Low Dose | Any AIN457 High Dose | Any AIN457 Dose | Placebo | Etanercept |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 17/56 | 25/58 | 42/114 | 1/41 | 11/41 |
| TonsillitisInfections and infestations | 11/56 | 7/58 | 18/114 | 0/41 | 1/41 |
| HeadacheNervous system disorders | 11/56 | 11/58 | 22/114 | 4/41 | 4/41 |
| PharyngitisInfections and infestations | 9/56 | 8/58 | 17/114 | 4/41 | 3/41 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/56 | 9/58 | 13/114 | 0/41 | 2/41 |
| AcneSkin and subcutaneous tissue disorders | 8/56 | 5/58 | 13/114 | 1/41 | 0/41 |
| DiarrhoeaGastrointestinal disorders | 7/56 | 7/58 | 14/114 | 0/41 | 1/41 |
| Upper respiratory tract infectionInfections and infestations | 7/56 | 3/58 | 10/114 | 3/41 | 3/41 |
| Glomerular filtration rate decreasedInvestigations | 7/56 | 4/58 | 11/114 | 0/41 | 1/41 |
| PsoriasisSkin and subcutaneous tissue disorders | 7/56 | 1/58 | 8/114 | 0/41 | 4/41 |
The randomized set was defined as all patients who were randomized. Mis-randomized patients were excluded from the randomized set. If patients were re screened and successfully randomized, they were included in the randomized set according to the treatment assigned in the last randomization.
| Age, Continuous(Years) | AIN457 Low Dose | AIN457 High Dose | Placebo | Etanercept | Total |
|---|---|---|---|---|---|
| Mean | 13.7 ± 2.92 | 13.2 ± 3.21 | 13.7 ± 3.27 | 13.5 ± 2.94 | 13.5 ± 3.06 |
| Age, Customized(Participants) | AIN457 Low Dose | AIN457 High Dose | Placebo | Etanercept | Total |
|---|---|---|---|---|---|
| <12 years | 8 | 9 | 10 | 10 | 37 |
| >=12 years | 32 | 31 | 31 | 31 | 125 |
| Sex: Female, Male(Participants) | AIN457 Low Dose | AIN457 High Dose | Placebo | Etanercept | Total |
|---|---|---|---|---|---|
| Female | 27 | 23 | 22 | 25 | 97 |
| Male | 13 | 17 | 19 | 16 | 65 |
| Race/Ethnicity, Customized(Participants) | AIN457 Low Dose | AIN457 High Dose | Placebo | Etanercept | Total |
|---|---|---|---|---|---|
| Caucasian | 34 | 34 | 36 | 30 | 134 |
| Black | 1 | 1 | 0 | 0 | 2 |
| Asian | 1 | 2 | 1 | 3 | 7 |
| Native American | 3 | 3 | 3 | 8 | 17 |
| Other | 1 | 0 | 1 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Sep 2015 to primary completion in Dec 2018, 38 months.
Results were first posted in Aug 2021, 2 years 8 months after primary completion. A results delay was requested in Aug 2019.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 38 months is above that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.